Loading...

LifeMD, Inc.

LFMDNASDAQ
Healthcare
Medical - Pharmaceuticals
$4.57
$-0.07(-1.51%)
U.S. Market opens in 11h 40m

LifeMD, Inc. Fundamental Analysis

LifeMD, Inc. (LFMD) shows moderate financial fundamentals with a PE ratio of -35.58, profit margin of -2.55%, and ROE of -1.18%. The company generates $0.2B in annual revenue with strong year-over-year growth of 39.27%.

Key Strengths

Cash Position17.25%
PEG Ratio-0.45

Areas of Concern

ROE-1.18%
Operating Margin-0.61%
We analyze LFMD's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -75.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-75.7/100

We analyze LFMD's fundamental strength across five key dimensions:

Efficiency Score

Weak

LFMD struggles to generate sufficient returns from assets.

ROA > 10%
-8.51%

Valuation Score

Excellent

LFMD trades at attractive valuation levels.

PE < 25
-35.58
PEG Ratio < 2
-0.45

Growth Score

Excellent

LFMD delivers strong and consistent growth momentum.

Revenue Growth > 5%
39.27%
EPS Growth > 10%
24.29%

Financial Health Score

Excellent

LFMD maintains a strong and stable balance sheet.

Debt/Equity < 1
0.27
Current Ratio > 1
1.25

Profitability Score

Weak

LFMD struggles to sustain strong margins.

ROE > 15%
-117.74%
Net Margin ≥ 15%
-2.55%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is LFMD Expensive or Cheap?

P/E Ratio

LFMD trades at -35.58 times earnings. This suggests potential undervaluation.

-35.58

PEG Ratio

When adjusting for growth, LFMD's PEG of -0.45 indicates potential undervaluation.

-0.45

Price to Book

The market values LifeMD, Inc. at 9.21 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

9.21

EV/EBITDA

Enterprise value stands at 31.80 times EBITDA. This signals the market has high growth expectations.

31.80

How Well Does LFMD Make Money?

Net Profit Margin

For every $100 in sales, LifeMD, Inc. keeps $-2.55 as profit after all expenses.

-2.55%

Operating Margin

Core operations generate -0.61 in profit for every $100 in revenue, before interest and taxes.

-0.61%

ROE

Management delivers $-1.18 in profit for every $100 of shareholder equity.

-1.18%

ROA

LifeMD, Inc. generates $-8.51 in profit for every $100 in assets, demonstrating efficient asset deployment.

-8.51%

Following the Money - Real Cash Generation

Operating Cash Flow

LifeMD, Inc. generates limited operating cash flow of $8.49M, signaling weaker underlying cash strength.

$8.49M

Free Cash Flow

LifeMD, Inc. produces free cash flow of $15.07M, offering steady but limited capital for shareholder returns and expansion.

$15.07M

FCF Per Share

Each share generates $0.31 in free cash annually.

$0.31

FCF Yield

LFMD converts 6.69% of its market value into free cash.

6.69%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-35.58

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.45

vs 25 benchmark

P/B Ratio

Price to book value ratio

9.21

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.93

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.27

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.25

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-1.18

vs 25 benchmark

ROA

Return on assets percentage

-0.09

vs 25 benchmark

ROCE

Return on capital employed

-0.05

vs 25 benchmark

How LFMD Stacks Against Its Sector Peers

MetricLFMD ValueSector AveragePerformance
P/E Ratio-35.5828.92 Better (Cheaper)
ROE-117.74%643.00% Weak
Net Margin-2.55%-45024.00% (disorted) Weak
Debt/Equity0.270.34 Neutral
Current Ratio1.254.50 Neutral
ROA-8.51%-16474.00% (disorted) Weak

LFMD outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews LifeMD, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

309.38%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

-28.58%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

1573.66%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ